ExpreS2ion Biotechnologies

{{short description|Danish biotechnology company}}

{{Infobox company

|logo = File:ExpreS2ion Biotechnologies logo.png

|name = ExpreS2ion Biotechnologies ApS

|type =

|traded_as = Nasdaq First North: [http://www.nasdaqomxnordic.com/aktier/microsite?languageId=1&Instrument=SSE125185= EXPRS2]

|foundation = 2010

|location = Hørsholm, Denmark

|key_people = Martin Roland Jensen (Chairman)
Bent U. Frandsen (CEO)

|industry = Biotechnology

|products = Vaccines and immunotherapy products

|parent = ExpreS2ion Biotech Holding AB

|homepage = [https://expres2ionbio.com/ www.expres2ionbio.com]

|num_employees =

}}

ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.{{cite web |title=The race to develop a coronavirus vaccine |url=https://eandt.theiet.org/content/articles/2020/04/the-race-to-develop-a-coronavirus-vaccine/ |website=Engineering & Technology |date=13 April 2020 |accessdate=25 April 2020}}

ExpreS2ion is part of the PREVENT-nCoV consortium comprising AdaptVac (a joint-venture between ExpreS2ion Biotechnologies and the University of Copenhagen spin-out NextGen Vaccines), Leiden University Medical Center, Institute for Tropical Medicine Tübingen, the Department of Immunology and Microbiology (ISIM) at the University of Copenhagen, and the Laboratory of Virology at Wageningen University and Research.{{cite web |title=ExpreS2ion announces selection of AGC Biologics as manufacturing partner for the COVID-19 vaccine and provides update to the program |url=https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-selection-of-agc-biologics-as-manufacturing-partner-for-the-covid-19-vaccine-an,c3094798 |website=Cision |accessdate=25 April 2020}} In March 2020 the consortium was awarded an EU Horizon 2020 grant of €2.7million for the development of a COVID-19 vaccine candidate, of which ExpreS2ion was funded with €0.88million.{{cite web |title=PREVENT-nCoV consortium announces EU grant award for COVID-19 vaccine development programme |url=https://www.medizin.uni-tuebingen.de/files/view/W0nPpDMa6lLgzbJo9VGLXAbO/200309%20Press%20release%20Covid-19%20consortium_final.pdf |accessdate=25 April 2020}}{{cite web |title=ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme |url=https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-eu-grant-award-for-the-covid-19-vaccine-development-programme,c3054055 |website=Cision |accessdate=25 April 2020}}